Advancing the
Power of Non-Viral
Gene Therapy
Transforming the treatment of genetic disease through STELLAR™, a first-in-class non-viral gene delivery platform designed for safe, repeatable, and durable expression.
Patients Need a Safe, Non-Viral Approach to Gene Therapy:
The current issues with gene therapy are that most approaches are viral, constructed through adeno-associated virus or “AAV’s”. These carry several issues related to immune responses, dose-related toxicities, limited packaging capacity (impacting delivery), and costly and complicated manufacturing processes.
Copernicus has solved the current issues that arise from AAV gene therapy by creating the STELLAR platform, which allows for a non-viral approach with nucleic acids providing more seamless delivery without payload size constraints, no issues related to viral vector toxicity, and off-the-shelf cGMP grade components, creating a more robust, efficient, and cost-effective manufacturing process.
Why is Copernicus Therapeutics the
Next Best Thing in Gene Therapy?
The Unmet Need in
Cystic Fibrosis
We are tackling a new approach to treating Cystic Fibrosis and that is restoring normal CFTR function.
Many people do not know that Cystic Fibrosis ("CF") affects more than 85,000 patients worldwide. While existing therapies target specific mutations, there are more than 2,500 mutations of CF and there is no therapy that can address all of them.
Copernicus’ lead asset, CFx, aims to restore normal CFTR function regardless of genetic variant – offering a potentially curative, mutation-agnostic therapy that can be viewed as “one size fits all”.
